EMBL researchers use mass spectrometry data to analyze effects of cancer drugs
Researchers at EMBL's European Bioinformatics Institute (EMBL-EBI) have developed a new method for studying the targets and effects of cancer drugs using data from discovery mass spectrometry (MS) experiments.